These findings are consistent with the 53% RR recently reported in HER2-positive advanced gastroesophageal adenocarcinoma cancer using capecitabine and oxaliplatin plus lapatinib.32 In addition, the 80% RR to targeting ctDNA-detected ERBB2 amplification in GC here is similar to the RR reported with the same ctDNA test in metastatic breast cancer, where six (86%) of seven patients receiving combination anti-HER2 therapy responded.25 This evidence concerns the gene ERBB2 and gastric cancer.